Yes, the FDA accepts clinical trial data from Latin America when studies adhere to FDA regulations, including 21 CFR 312.120 for non-IND studies and 21 CFR 814.15 for medical devices, and demonstrate compliance with Good Clinical Practice (GCP) such as ICH-GCP guidelines.
The U.S. Food and Drug Administration (FDA) consistently accepts clinical trial data from Latin American countries for regulatory submissions, provided these studies are conducted in accordance with rigorous ethical and scientific standards. This acceptance is crucial for medical device and pharmaceutical sponsors looking to leverage the unique advantages of the Latin American clinical research landscape.
The regulatory framework supporting FDA's acceptance of foreign clinical data is well-established, primarily outlined in 21 CFR 312.120 for drug studies not conducted under an IND and 21 CFR 814.15 for medical device studies submitted in support of a PMA or IDE. These regulations emphasize the necessity for studies to be conducted in accordance with Good Clinical Practice (GCP), including review by an independent ethics committee and informed consent from all participants.
21 CFR 312.120 – Foreign Clinical Studies Not Conducted Under an IND
This regulation specifies the conditions under which the FDA will accept foreign clinical studies not conducted under an IND in support of an IND or a New Drug Application (NDA). Key requirements include:
21 CFR 814.15 – PMA and IDE Foreign Data
For medical devices, 21 CFR 814.15 addresses the acceptance of foreign clinical data submitted in support of a Premarket Approval (PMA) application or an Investigational Device Exemption (IDE). The conditions are similar to those for drug studies:
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines are globally recognized ethical and scientific quality standards for designing, conducting, recording, and reporting trials that involve the participation of human subjects. Adherence to ICH-GCP is a critical factor for FDA acceptance of foreign clinical data.
Many Latin American countries have adopted or extensively incorporated ICH-GCP principles into their national regulatory frameworks. Regulatory bodies such as INVIMA in Colombia, COFEPRIS in Mexico, ANVISA in Brazil, and ANMAT in Argentina actively promote and enforce GCP compliance. This commitment ensures that clinical trials conducted in these regions meet the international standards required by the FDA.
bioaccess® works exclusively with sites and Principal Investigators (PIs) who are rigorously trained and experienced in ICH-GCP, ensuring all submitted data meets FDA requirements. With over 200+ PIs across 10 countries, bioaccess® has a proven track record of facilitating successful FIH trials compliant with global standards.
The FDA frequently conducts inspections of foreign clinical sites, including those in Latin America, to ensure data integrity and compliance with regulatory requirements. These inspections are a critical component of the FDA's oversight and validation process. The agency's capacity and willingness to inspect sites globally underscores its commitment to ensuring the reliability of data used in regulatory submissions, regardless of geographic origin.
While specific client names or devices are proprietary, it is publicly recognized that numerous medical devices and drugs have received FDA clearance or approval with pivotal or supportive data originating from clinical trials conducted in Latin America. These successes demonstrate the FDA's confidence in the quality and reliability of data from these regions when regulatory and ethical standards are met.
Sponsors leveraging bioaccess®'s expertise have successfully navigated the FDA's requirements, demonstrating the viability and strategic advantage of conducting FIH medical device trials in Latin America. Our 50+ clients have benefited from a process that is 40% faster than US/EU trials, with a 30% lower per-patient cost, and an average 6-8 week FIH start-up time.
The FDA's Diversity Action Plan emphasizes the importance of enrolling diverse patient populations in clinical trials to ensure that medical products are safe and effective across various demographic groups. Latin America offers a unique advantage in this regard, providing access to ethnically and genetically diverse populations that are often underrepresented in clinical trials conducted in the U.S. and Europe.
By including data from Latin American patient populations, sponsors can better meet the FDA's diversity objectives, leading to more generalizable and equitable healthcare solutions. This strategic alignment further enhances the value proposition of conducting clinical trials in the region.
| Feature | Latin America Advantage | Impact on FDA Submission |
|---|---|---|
| Patient Enrollment | Faster enrollment rates (40% faster than US/EU), access to larger naive patient pools. | Expedited trial timelines, supporting quicker submission to FDA. |
| Cost-Effectiveness | Significantly lower per-patient costs (30% lower than US/EU). | Optimizes R&D budgets, allowing for more comprehensive data collection for FDA. |
| Diversity | Diverse patient populations, aligning with FDA Diversity Action Plan. | Meets FDA requirements for diverse representation, enhancing generalizability of data. |
| Regulatory Efficiency | Streamlined regulatory processes in several countries (6-8 week FIH start-up). | Enables rapid study initiation, accelerating data generation for FDA review. |
| Investigator Expertise | Highly qualified and experienced PIs (200+ PIs) with strong GCP compliance. | Ensures high-quality data and study conduct meeting FDA standards. |
The FDA unequivocally accepts clinical trial data from Latin America, provided these studies adhere to stringent ethical and scientific standards, particularly 21 CFR 312.120 and 21 CFR 814.15, and demonstrate compliance with ICH-GCP. The robust regulatory frameworks in Latin American countries, coupled with the region's capacity for rapid and diverse patient enrollment, present a compelling case for sponsors seeking efficient and high-quality data for FDA submissions. bioaccess® stands ready to guide device sponsors through this advantageous landscape, leveraging its deep regional expertise and proven track record with over 50+ clients and 10 countries to accelerate FIH medical device trials.
21 CFR 312.120 is an FDA regulation detailing the conditions under which the agency will accept foreign clinical studies not conducted under an Investigational New Drug (IND) application. For such data to be accepted, the studies must adhere to the Declaration of Helsinki's ethical principles, comply with Good Clinical Practice (GCP), and allow the FDA access for validation through on-site inspections if necessary. This regulation ensures the integrity and reliability of drug study data originating from outside the U.S. for FDA submissions.
Yes, the FDA conducts inspections of clinical trial sites in Latin America, just as it does in other regions globally. These inspections are a vital part of the FDA's process for validating data submitted from foreign clinical studies. The purpose is to ensure that the studies were conducted in compliance with applicable regulations, ethical standards, and Good Clinical Practice (GCP), thereby verifying the reliability and authenticity of the data used in support of regulatory applications.
ICH-GCP (International Council for Harmonisation – Good Clinical Practice) compliance is crucial for FDA acceptance of Latin American clinical data. Adherence to these international ethical and scientific quality standards demonstrates that trials were designed, conducted, recorded, and reported rigorously, protecting human subjects and ensuring data integrity. Most Latin American countries' regulatory bodies, like INVIMA and COFEPRIS, have adopted ICH-GCP, facilitating data acceptance by the FDA. bioaccess® exclusively partners with ICH-GCP trained investigators.
Latin American patient diversity is highly beneficial for FDA submissions as it aligns with the FDA's Diversity Action Plan, which emphasizes including diverse populations in clinical trials. This ensures that medical products are safe and effective across various demographic groups. By enrolling participants from Latin America's diverse ethnic and genetic backgrounds, sponsors can generate more comprehensive and generalizable data, strengthening their submissions and addressing potential disparities in treatment efficacy across different populations.
Key advantages of conducting FIH medical device trials in Latin America for FDA submission include significantly faster patient enrollment (40% faster than US/EU), which accelerates trial timelines. The region also offers a 30% lower per-patient cost, optimizing research budgets. Additionally, Latin America provides access to diverse patient populations, aligning with FDA's diversity initiatives, and boasts streamlined regulatory processes leading to 6-8 week FIH start-up times. These factors, combined with experienced PIs, enhance the efficiency and quality of data for FDA review.